Gilead tops estimates as HCV sales level off

Gilead Sciences Inc. (NASDAQ:GILD) reported $4.8 billion in HCV sales in 3Q15, up 70% from $2.8 billion in 3Q14. Quarterly sales of Harvoni ledipasvir/ sofosbuvir were $3.3 billion, while sales of Sovaldi sofosbuvir declined to $1.5 billion in 3Q15 from $2.8 billion in 3Q14.

HCV sales were down sequentially from $4.9 billion in 2Q15, as Harvoni sales dipped from $3.6 billion while Sovaldi sales rose from $1.3 billion. ...